Enhancement of the endogenous opioid system by ketamine

氯胺酮增强内源性阿片系统

• 批准号: 10717708
• 负责人: Lakshmi A Devi
• 金额: $ 59.17万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10717708
• 关键词: Absence of pain sensation; Acute; Acute Pain; Adenylate Cyclase; Affect; Analgesics; Anesthetics; Animals; Antidepressive Agents; Arrestins; Binding; Biological; Biological Process; Brain; Brain region; Cell Surface Receptors; Cells; Clinical effectiveness; Complex; Corpus striatum structure; Cryoelectron Microscopy; Cultured Cells; Data; Disease; Dose; Dynorphins; Electrophysiology (science); Fentanyl; Functional disorder; GTP-Binding Proteins; General anesthetic drugs; Glutamate Receptor; Health; Hour; Human; Hypothalamic structure; Ketamine; Laboratories; Laboratory Finding; Leucine Enkephalin; Ligands; Location; Long-Term Effects; Major Depressive Disorder; Measures; Mediating; Membrane; Mental Depression; Methionine Enkephalin; Morphine; Mus; N-Methyl-D-Aspartate Receptors; Naltrexone; Neurons; Neuropeptides; Neurotransmitters; Opioid; Opioid Antagonist; Opioid Peptide; Opioid Receptor; Pain; Peptides; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Phosphotransferases; Plasma; Preparation; Production; Protein Precursors; Receptor Inhibition; Receptor Signaling; Rewards; Rodent; Role; Signal Transduction; Slice; Solid; Stereoisomer; Structure; Synapses; System; Testing; Time; Tissues; Transducers; Ventral Tegmental Area; antagonist; antidepressant effect; beta-Endorphin; chronic pain; clinically relevant; comorbidity; delta opioid receptor; economic cost; effective therapy; endogenous opioids; gamma-Aminobutyric Acid; in vivo; insight; kappa opioid receptors; molecular drug target; mu opioid receptors; norketamine; novel therapeutics; opioid use disorder; positive allosteric modulator; radioligand; receptor; receptor-mediated signaling; recruit; social; synergism; synthetic drug

Project Summary: The endogenous opioid system is involved in many diverse biological processes and contributes to a range of disorders that have enormous health and societal consequences such as opioid use disorder, pain, and major depressive disorder. The endogenous opioid system consists of dozens of opioid peptides derived from three distinct precursor proteins, and three cell surface receptors that are activated by these peptides as well as by opiates and synthetic drugs. Recently, ketamine has emerged as an effective treatment for both major depressive disorder and chronic pain, and may also be effective in treating opioid use disorder. While ketamine’s anesthetic actions are due to its inhibition of a subtype of glutamate receptors, the mechanisms of its other biological effects remain elusive. Studies from our laboratory and other groups have found that ketamine interacts with the endogenous opioid system, however the full scope of these interactions is not known. Moreover, a single dose of ketamine produces rapid effects within minutes/hours, as well as sustained effects that last days/weeks. The long-term effects are remarkable and unlike the anesthetic action of ketamine which correlates with plasma levels. Our central hypothesis is that ketamine interacts with the endogenous opioid system to produce both rapid and long-term effects. This hypothesis is supported by our preliminary data showing that ketamine acts as a positive allosteric modulator of opioid receptors to synergize with endogenous opioid peptides. Our central hypothesis will be tested in three Specific Aims that are highly interrelated. Aim 1A will characterize the activity of ketamine as an allosteric modulator of the endogenous opioid system using cultured cells and membrane preparations. These studies will investigate short- and long-term effects of ketamine (including racemic ketamine and the stereoisomers S- and R-ketamine) and major bioactive metabolites (norketamine and hydroxynorketamine). Using electrophysiology in brain slices, Aim 1B will measure acute effects of ketamine on opioid receptor-mediated signaling and persistent changes induced by in vivo ketamine administration. Aim 2A will test the interaction of ketamine with highly purified preparations of opioid receptors. Aim 2B will determine the cryoEM structure of the mu opioid receptor in complex with ketamine and a peptide ligand. Aim 3 will examine the effect of ketamine on the levels of endogenous opioid peptides in mouse brain. Collectively, these studies will provide a solid understanding of the interactions of ketamine with the endogenous opioid system, providing mechanisms to account for the rapid and long-term effects of this drug. Historically, understanding the molecular targets of drugs have led to insights into the pathophysiology of disease and novel therapeutics. Because little is known regarding the mechanism(s) of ketamine as an antidepressant and analgesic, and the comorbidity of these diseases with opioid use disorder, our studies to determine the interaction of ketamine and the endogenous opioid system are highly relevant to human health.

项目概要： 内源性阿片系统参与许多不同的生物过程，并有助于一系列 具有巨大健康和社会后果的疾病，例如阿片类药物使用障碍、疼痛和重大疾病 内源性阿片类药物系统由来自三种阿片类药物的数十种肽组成。 不同的前体蛋白，以及由这些肽以及由这些肽激活的三种细胞表面受体 最近，氯胺酮已成为治疗这两种主要药物的有效方法。 抑郁症和慢性疼痛，也可能有效治疗阿片类药物使用障碍。 麻醉作用是由于其抑制谷氨酸受体的亚型，其其他机制 我们实验室和其他小组的研究发现氯胺酮的生物效应仍然难以捉摸。 与内源性阿片系统相互作用，但这些相互作用的全部范围尚不清楚。 此外，单剂量的氯胺酮在几分钟/几小时内产生快速作用，以及持续作用 持续数天/数周的长期效果是显着的，与氯胺酮的麻醉作用不同。 我们的中心假设是氯胺酮与内源性相互作用。 我们的初步支持了阿片类药物系统产生快速和长期作用的假设。 数据显示，氯胺酮作为阿片受体的正变构调节剂，与 内源性阿片肽。 我们的中心假设将在三个高度相关的具体目标中得到检验。 使用培养物表征氯胺酮作为内源性阿片类药物系统变构调节剂的活性 这些研究将调查氯胺酮的短期和长期影响。 （包括外消旋氯胺酮和立体异构体 S- 和 R-氯胺酮）和主要生物活性代谢物 （去甲氯胺酮和羟基去甲氯胺酮）利用脑切片中的电生理学，Aim 1B 将测量急性。 氯胺酮对阿片受体介导的信号传导以及体内氯胺酮诱导的持续变化的影响 目标 2A 将测试氯胺酮与高度纯化的阿片受体制剂的相互作用。 目标 2B 将确定 mu 阿片受体与氯胺酮和肽复合物的冷冻电镜结构 目标 3 将检查氯胺酮对小鼠大脑内源性阿片肽水平的影响。 总的来说，这些研究将为氯胺酮与氯胺酮之间的相互作用提供深入的了解。 内源性阿片类药物系统，提供了解释该药物快速和长期作用的机制。 从历史上看，了解药物的分子靶标有助于深入了解疾病的病理生理学 因为人们对氯胺酮作为抗抑郁药的机制知之甚少。 和镇痛药，以及这些疾病与阿片类药物使用障碍的合并症，我们的研究确定了 氯胺酮与内源性阿片系统的相互作用与人类健康高度相关。